abiraterone has been researched along with flutamide in 8 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (flutamide) | Trials (flutamide) | Recent Studies (post-2010) (flutamide) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 2,808 | 429 | 610 |
| Protein | Taxonomy | abiraterone (IC50) | flutamide (IC50) |
|---|---|---|---|
| Androgen receptor | Homo sapiens (human) | 1.348 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Endo, S; Fujii, S; Fujimoto, N; Gouda, H; Hu, D; Iguchi, K; Ikari, A; Irie, K; Kawai, M; Matsukawa, T; Matsunaga, T; Nakayama, T; Oguri, H; Okada, T; Segawa, J; Toyooka, N; Xia, S | 1 |
| Barrie, SE; Dowsett, M; Goddard, PM; Haynes, BP; Jarman, M; Potter, GA | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Bristow, RG; Dal Pra, A; Locke, JA; Supiot, S; Warde, P | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
| Anai, S; Fujimoto, K; Inoue, T; Miyake, M; Nakai, Y; Tanaka, N | 1 |
1 review(s) available for abiraterone and flutamide
| Article | Year |
|---|---|
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiotherapy, Image-Guided; Risk Assessment; Treatment Outcome | 2015 |
7 other study(ies) available for abiraterone and flutamide
| Article | Year |
|---|---|
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice, Inbred BALB C; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays | 2020 |
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
Topics: Abiraterone Acetate; Adrenal Glands; Aldehyde-Lyases; Androgens; Androstadienes; Androstenes; Androstenols; Animals; Cytochrome P-450 Enzyme Inhibitors; Flutamide; Guinea Pigs; Ketoconazole; Kidney; Luteinizing Hormone; Male; Mice; Orchiectomy; Organ Size; Prostate; Seminal Vesicles; Steroid 17-alpha-Hydroxylase; Testis; Testosterone | 1994 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2018 |